| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = -$3,467 ) |
| | 2024 | 2019 | SIGHTGENE INC | 605 E HUNTINGTON DR | MONROVIA | CA | 91016-6353 | LOS ANGELES | USA | R01EY026935 | Fibrillin-1 and TGFB2 Abnormality Models POAG Pathogenesis and Treatment | 000 | 4 | NIH | 2/26/2024 | -$3,467 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2019 | SIGHTGENE INC | 605 E HUNTINGTON DR | MONROVIA | CA | 91016-6353 | LOS ANGELES | USA | R21EY029062 | Contractile Modulation of Distal Aqueous Humor Drainage | 000 | 3 | NIH | 10/31/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2019 | SIGHTGENE, INC. | 605 E HUNTINGTON DR STE 103 | MONROVIA | CA | 91016-6353 | LOS ANGELES | USA | R01EY026935 | Fibrillin-1 and TGFB2 Abnormality Models POAG Pathogenesis and Treatment | 000 | 4 | NIH | 4/6/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2019 | SIGHTGENE, INC. | 605 E HUNTINGTON DR STE 103 | MONROVIA | CA | 91016-6353 | LOS ANGELES | USA | R21EY029062 | Contractile Modulation of Distal Aqueous Humor Drainage | 000 | 3 | NIH | 4/12/2021 | $0 |
| | 2021 | 2019 | SIGHTGENE, INC. | 605 E HUNTINGTON DR STE 103 | MONROVIA | CA | 91016-6353 | LOS ANGELES | USA | R01EY026935 | Fibrillin-1 and TGFB2 Abnormality Models POAG Pathogenesis and Treatment | 000 | 4 | NIH | 4/12/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $630,731 ) |
| | 2020 | 2019 | SIGHTGENE, INC. | 605 E HUNTINGTON DR STE 103 | MONROVIA | CA | 91016-6353 | LOS ANGELES | USA | R21EY029062 | Contractile Modulation of Distal Aqueous Humor Drainage | 005 | 3 | NIH | 9/12/2020 | $109,452 |
| | 2020 | 2019 | SIGHTGENE, INC. | 605 E HUNTINGTON DR STE 103 | MONROVIA | CA | 91016-6353 | LOS ANGELES | USA | R21EY029062 | Contractile Modulation of Distal Aqueous Humor Drainage | 002 | 3 | NIH | 8/25/2020 | $0 |
| | 2020 | 2019 | SIGHTGENE, INC. | 605 E HUNTINGTON DR STE 103 | MONROVIA | CA | 91016-6353 | LOS ANGELES | USA | R21EY029062 | Contractile Modulation of Distal Aqueous Humor Drainage | 001 | 3 | NIH | 6/2/2020 | $99,856 |
| | 2020 | 2019 | SIGHTGENE, INC. | 605 E HUNTINGTON DR STE 103 | MONROVIA | CA | 91016-6353 | LOS ANGELES | USA | R01EY026935 | Fibrillin-1 and TGFB2 Abnormality Models POAG Pathogenesis and Treatment | 005 | 4 | NIH | 9/12/2020 | $242,091 |
| | 2020 | 2019 | SIGHTGENE, INC. | 605 E HUNTINGTON DR STE 103 | MONROVIA | CA | 91016-6353 | LOS ANGELES | USA | R01EY026935 | Fibrillin-1 and TGFB2 Abnormality Models POAG Pathogenesis and Treatment | 002 | 4 | NIH | 8/25/2020 | $0 |
| | 2020 | 2019 | SIGHTGENE, INC. | 605 E HUNTINGTON DR STE 103 | MONROVIA | CA | 91016-6353 | LOS ANGELES | USA | R01EY026935 | Fibrillin-1 and TGFB2 Abnormality Models POAG Pathogenesis and Treatment | 001 | 4 | NIH | 6/8/2020 | $179,332 |
|
|
